Kyverna Therapeutics, Inc. KYTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$39.73M-5.1% | -$37.8M-2.8% | -$36.79M+12.6% | -$42.08M+5.7% | -$44.64M-19.1% | ||
| $351K-4.6% | $368K-11.3% | $415K-19.4% | $515K+2.8% | $501K-11.0% | ||
| $3.17M+17.4% | $2.7M+0.1% | $2.7M+7.2% | $2.52M+16.5% | $2.16M+56.4% | ||
| $6.28M+192% | $2.15M+132% | -$6.8M-583% | $1.41M-62.8% | $3.78M— | ||
| -$6.88M-327% | $3.03M+52.3% | $1.99M+5.1% | $1.89M+205% | -$1.8M-507% | ||
| $5K— | —— | $958K— | —— | $515K-46.4% | ||
| -$503K+40.4% | -$844K-9.0% | -$774K-2.1% | -$758K+21.3% | -$963K-48.8% | ||
| -$41.6M-24.1% | -$33.53M+22.6% | -$43.32M-35.6% | -$31.95M+28.9% | -$44.92M-21.2% | ||
| —— | —— | $2K-50.0% | $4K— | $0-100% | ||
| -$50.2M— | —— | $22.56M-22.7% | $29.17M+423% | $5.58M— | ||
| —— | $6.18M0.0% | $6.18M0.0% | $6.18M0.0% | $6.18M— | ||
| $243K-98.4% | $15.29M+826% | $1.65M— | $0-100% | $3K+101% | ||
| $86K+1.2% | $85K-29.2% | $120K-54.2% | $262K-23.2% | $341K+38.1% | ||
| —— | —— | —— | —— | —— | ||
| -$101K-100% | $140.74M+9,359% | $1.49M+329% | -$649K-56.8% | -$414K— | ||
| -$91.9M-202% | $89.93M+567% | -$19.28M-462% | -$3.43M+91.4% | -$39.75M— | ||
| $568K+53.5% | $370K+4,525% | $8K-55.6% | $18K-5.3% | $19K-29.6% | ||
| $730K-46.6% | $1.37M-12.7% | $1.57M-15.0% | $1.84M-12.7% | $2.11M-5.6% | ||
| $0— | —— | —— | —— | $648K— | ||
| —— | -$625K0.0% | -$625K0.0% | -$625K0.0% | -$625K— | ||
| -$6.88M-327% | $3.03M+52.3% | $1.99M+5.1% | $1.89M+205% | -$1.8M-507% | ||
| -$503K+40.4% | -$844K-9.0% | -$774K-2.1% | -$758K+21.3% | -$963K-48.8% | ||
| -$4.35M-576% | -$644K+45.1% | -$1.17M-135% | $3.32M+244% | -$2.31M-130% | ||
| -$66K-13.8% | -$58K— | —— | -$2.35M-719% | $380K-54.5% | ||
| $114K— | —— | —— | —— | $0— | ||
| $619K-17.4% | $749K+2.3% | $732K+2.4% | $715K+1.6% | $704K+2.8% | ||
| $86K+1.2% | $85K-29.2% | $120K-54.2% | $262K-23.2% | $341K+38.1% | ||
| $189K+278% | $50K+16.3% | $43K-15.7% | $51K— | $0— | ||
| $69K+9.5% | $63K— | $0-100% | $336K+342% | $76K— | ||
| —— | $98.97M— | $0— | $0— | $0— | ||
| -$503K+40.4% | -$844K-9.0% | -$774K-2.1% | -$758K+21.3% | -$963K-48.8% | ||
| $5.24M+2,603% | $194K— | $0— | $0— | $0— | ||
| $123K— | —— | —— | —— | $217K— | ||
| —— | -$33.53M+22.6% | -$43.32M-35.6% | -$31.95M+28.9% | -$44.92M-19.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kyverna Therapeutics, Inc. generate?
- Kyverna Therapeutics, Inc. (KYTX) generated -$150.4M in operating cash flow over the trailing twelve months.
- What is Kyverna Therapeutics, Inc.'s free cash flow?
- After $538.0K of capital expenditures, Kyverna Therapeutics, Inc.'s free cash flow was -$153.7M over the trailing twelve months, down 32.0% year over year.
- Where does Kyverna Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.